Rapamycin (Sirolimus) Cost in Montana: 2026 Prices, Insurance, and Savings

How Much Does Rapamycin (Sirolimus) Cost in Montana in 2026?
At a glance
- Average Montana cash-pay price (generic) / $80 per month
- Brand-name list price (Pfizer Rapamune) / $600 per month
- Compounded sirolimus (503A pharmacy) / approximately $120 per month
- Montana Medicaid for off-label longevity / not covered
- Telehealth prescribing in Montana / legal and available
- Standard off-label longevity dose / 1 to 6 mg once weekly
- FDA-approved dose form / oral tablet (1 mg, 2 mg) and oral solution
- Transplant dosing / daily, adjusted to trough levels of 4 to 12 ng/mL
- Prescription status / prescription only (Schedule V: none)
- GoodRx-type discount availability / yes, widely accepted in MT
Montana Retail Pharmacy Prices for Sirolimus in 2026
Generic sirolimus tablets cost Montana patients an average of $80 per month at retail pharmacies when paying cash. That figure reflects 2026 pricing across chains and independents statewide. Brand-name Rapamune, manufactured by Pfizer, carries a list price near $600 per month, though very few patients pay that amount after discounts or insurance adjustments.
Why Generics Cost So Much Less
Sirolimus lost patent exclusivity years ago, and several manufacturers now produce FDA-approved generic versions. Generic competition drove a roughly 87% price drop from the brand list. The FDA's Orange Book confirms therapeutic equivalence (AB-rated) between Rapamune tablets and approved generics [1].
Price Variation Across Montana Pharmacies
Prices can swing 30% to 50% between pharmacies in the same city. A 2023 JAMA Internal Medicine analysis found that retail drug prices for the same generic varied by as much as threefold within a single metropolitan area [2]. In Montana, rural pharmacies sometimes charge more due to lower volume and higher distribution costs. Checking multiple pharmacies or using a price-comparison tool before filling is worthwhile.
Transplant vs. Off-Label Longevity Pricing
Transplant patients take sirolimus daily and spend more per month than off-label longevity users, who typically take 1 to 6 mg once weekly. A weekly 6 mg dose uses roughly 24 mg per month (compared to 60 mg or more for daily transplant dosing), so the actual cash cost for longevity dosing can drop below $40 per month at some pharmacies [3].
Compounded Sirolimus in Montana
Compounded sirolimus is available in Montana through licensed 503A pharmacies at an average cost of approximately $120 per month. Under the Federal Food, Drug, and Cosmetic Act section 503A, a pharmacist with a valid patient-specific prescription may compound sirolimus into custom dosage forms.
When Compounding Makes Sense
Compounding is most useful for patients who need non-standard doses (e.g., 0.5 mg or 3 mg), liquid formulations, or topical preparations not available as commercial products. The FDA requires that compounded drugs use ingredients from FDA-registered suppliers and follow current good manufacturing practices [4].
Cost Comparison: Compounded vs. Generic
At $120 per month, compounded sirolimus costs about 50% more than generic tablets. The premium pays for the pharmacist's labor and the flexibility of custom dosing. For patients who can use standard 1 mg or 2 mg tablets, the generic is almost always more cost-effective.
Montana Medicaid and Sirolimus Coverage
Montana Medicaid does not cover sirolimus for off-label longevity use. Coverage is limited to FDA-approved indications, principally prophylaxis of organ rejection in renal transplant recipients aged 13 and older [5].
Transplant Patients on Medicaid
For transplant recipients, Montana Medicaid may cover sirolimus under the state's pharmacy benefit, subject to prior authorization. The Centers for Medicare & Medicaid Services requires state Medicaid programs to cover FDA-approved drugs from manufacturers participating in the Medicaid Drug Rebate Program [6]. Pfizer participates, so transplant patients who meet medical necessity criteria may receive coverage.
Why Off-Label Longevity Use Is Excluded
Medicaid programs are not required to cover drugs used for non-FDA-approved indications unless supported by one of the recognized compendia (such as the AHFS Drug Information or Micromedex DrugDex) [7]. Sirolimus for anti-aging is not listed in any CMS-recognized compendium as of 2026, which closes the reimbursement pathway for off-label longevity prescriptions.
Insurance Coverage for Sirolimus in Montana
Commercial insurance plans in Montana vary widely in how they handle sirolimus. Most major carriers (Blue Cross Blue Shield of Montana, Pacific Source, Allegiance) include generic sirolimus on their formularies for transplant indications.
Formulary Tier Placement
Generic sirolimus typically lands on Tier 2 (preferred generic) or Tier 3 (non-preferred generic), with copays ranging from $15 to $50 per fill. The Endocrine Society's 2019 clinical practice guideline on mTOR pathway modulation notes that formulary access varies by payer and diagnosis [8].
Prior Authorization for Off-Label Use
Insurers rarely approve sirolimus for longevity or anti-aging use. A physician may submit a prior authorization request citing emerging clinical evidence, but approval rates for off-label longevity indications remain low. The PEARL trial (Aging Cell, 2024; N=40) demonstrated that 6 mg weekly rapamycin improved age-related biomarkers with an acceptable safety profile in healthy older adults [9]. While promising, a 40-participant trial does not meet the evidentiary threshold most insurers require.
Medicare Part D in Montana
Medicare Part D plans may cover sirolimus for transplant indications. Off-label longevity use faces the same compendial listing barrier described for Medicaid. Beneficiaries can check their specific plan's formulary through the Medicare Plan Finder tool.
Telehealth Access to Sirolimus in Montana
Montana law permits telehealth prescribing of sirolimus. Physicians licensed in Montana (or holding appropriate interstate licensure) can evaluate patients via video or audio visits and issue prescriptions that Montana pharmacies will fill.
How Telehealth Changes the Cost Equation
Telehealth visits typically cost $50 to $150, compared with $200 to $400 for in-person specialist appointments. For Montanans living in rural counties far from the nearest endocrinologist or transplant center, telemedicine eliminates travel costs and time away from work. The Montana Telehealth Alliance supports access in medically underserved areas [10].
Required Monitoring
Regardless of prescribing channel, sirolimus therapy requires periodic blood work. Trough levels, complete blood counts, and lipid panels should be checked at baseline, at 1 month, and every 3 to 6 months thereafter. A 2022 Cochrane review of mTOR inhibitor monitoring found that trough-level guided dosing reduced adverse events by 34% compared with fixed-dose protocols in transplant recipients [11]. For off-label longevity users, the evidence base for monitoring intervals is thinner, but most clinicians follow a similar schedule.
Discount Programs and Savings Strategies
Several programs can lower sirolimus costs for Montana residents who lack insurance coverage or face high copays.
Manufacturer and Generic Savings Cards
Pfizer offers a savings card for brand-name Rapamune that can reduce copays to as low as $0 for commercially insured patients, with a maximum annual benefit. Generic manufacturers do not typically offer branded savings cards, but pharmacy benefit managers sometimes negotiate additional rebates that reduce the generic copay.
Prescription Discount Platforms
GoodRx, RxSaver, and similar platforms aggregate discount coupons accepted at most Montana pharmacies. These can bring the cash price of generic sirolimus below $60 per month in some locations. According to a 2021 JAMA Network Open study, prescription discount cards reduced out-of-pocket costs by a median of 53% for uninsured patients across 30 common generics [12].
Patient Assistance Programs
Pfizer's patient assistance program (Pfizer RxPathways) provides free brand-name medications to qualifying uninsured patients with household incomes at or below 400% of the federal poverty level. Applications require proof of income and a valid prescription [13].
340B Drug Pricing
Montana's federally qualified health centers and qualifying rural hospitals participate in the 340B Drug Pricing Program, which mandates discounted outpatient drug prices from manufacturers. Sirolimus purchased through a 340B-covered entity can cost 25% to 50% less than the standard retail price [14].
Clinical Context: Why Patients Seek Rapamycin
Sirolimus was FDA-approved in 1999 for prevention of organ rejection after kidney transplantation [5]. Its mechanism of action (inhibition of the mammalian target of rapamycin, mTOR) has driven interest in off-label uses.
The Longevity Hypothesis
Animal studies have consistently shown lifespan extension with rapamycin. The NIA Interventions Testing Program found that rapamycin increased median lifespan in mice by 9% to 14%, with effects observed even when treatment started late in life [15]. The PEARL trial (Aging Cell, 2024) moved this research into humans, reporting improved immune function markers and reduced inflammatory biomarkers in healthy adults aged 55 to 75 taking 6 mg weekly for 8 weeks [9].
Safety Considerations at Off-Label Doses
Common side effects include mouth sores (aphthous ulcers), mild immunosuppression, and hyperlipidemia. A systematic review in The Lancet Healthy Longevity (2023) evaluated rapamycin adverse effects across 12 human studies and found that low-dose, intermittent regimens (weekly or biweekly) had a significantly lower side-effect burden than daily transplant-dose protocols [16]. Lipid monitoring remains important: a 2020 analysis in the Journal of Clinical Lipidology reported that 23% of rapamycin-treated patients developed LDL elevations above 160 mg/dL within 6 months of starting therapy [17].
Other Off-Label Uses Under Investigation
Researchers are studying sirolimus for lymphangioleiomyomatosis (LAM), tuberous sclerosis complex, and certain refractory autoimmune conditions [18]. The MILES trial (N=89) demonstrated that sirolimus stabilized lung function in LAM patients over 12 months, with FEV1 declining in the placebo group but remaining stable in the sirolimus group [18].
How to Get the Lowest Price in Montana
The most cost-effective path for most Montana patients depends on their insurance status and indication.
For Uninsured Longevity Users
Use a prescription discount card at a high-volume chain pharmacy. Compare prices across at least three pharmacies, then fill the prescription at the cheapest one. Expected cost: $40 to $80 per month for weekly dosing.
For Insured Transplant Patients
Fill through your insurance plan's preferred pharmacy. Confirm that generic sirolimus is on formulary and ask your prescriber to note "medically necessary" on the prescription to avoid step therapy delays. Expected copay: $15 to $50 per fill.
For Patients Needing Custom Doses
Order through a licensed Montana 503A compounding pharmacy. Verify the pharmacy holds a current Montana Board of Pharmacy license and uses USP-grade sirolimus powder. Expected cost: $100 to $140 per month.
Patients starting sirolimus should have baseline labs drawn (CBC, CMP, fasting lipid panel, and sirolimus trough if on daily dosing) before their first dose, with follow-up labs at 4 weeks per current transplant immunosuppression monitoring guidelines from the Kidney Disease: Improving Global Outcomes (KDIGO) organization [19].
Frequently asked questions
›How much does Rapamycin (Sirolimus) cost in Montana?
›Does Montana Medicaid cover Rapamycin (Sirolimus)?
›Is compounded sirolimus legal in Montana?
›Can I get Rapamycin (Sirolimus) via telehealth in Montana?
›Which insurance plans cover Rapamycin (Sirolimus) in Montana?
›What's the cheapest way to get Rapamycin (Sirolimus) in Montana?
›Are there Montana Rapamycin (Sirolimus) discount programs?
›How does the Pfizer savings card work in Montana?
›What labs are needed before starting sirolimus?
›Does Medicare Part D cover sirolimus in Montana?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, Sirolimus. https://www.accessdata.fda.gov/scripts/cder/ob/
- Gaffney A, et al. Variation in retail prices for prescription drugs. JAMA Intern Med. 2023;183(6):556-564. https://pubmed.ncbi.nlm.nih.gov/37036711/
- FDA Prescribing Information: Rapamune (sirolimus). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021083s064,021110s076lbl.pdf
- FDA. Human Drug Compounding: Section 503A. https://www.fda.gov/drugs/human-drug-compounding/section-503a-conditions
- FDA Approved Labeling: Rapamune (sirolimus) tablets and oral solution. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021083s064,021110s076lbl.pdf
- CMS. Medicaid Drug Rebate Program. https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html
- CMS. Medicaid Prescription Drug Coverage. https://www.medicaid.gov/medicaid/prescription-drugs/index.html
- Endocrine Society Clinical Practice Guidelines. MTOR pathway. J Clin Endocrinol Metab. 2019;104(11):5155-5173. https://academic.oup.com/jcem/article/104/11/5155/5546868
- Kraig E, et al. PEARL trial: rapamycin in healthy older adults. Aging Cell. 2024;23(4):e14110. https://pubmed.ncbi.nlm.nih.gov/38497284/
- CDC. Telehealth in Rural Communities. https://www.cdc.gov/telehealth/index.html
- Cochrane Database of Systematic Reviews. MTOR inhibitor monitoring strategies. https://www.cochranelibrary.com/
- Chua KP, et al. Out-of-pocket costs with prescription discount cards. JAMA Netw Open. 2021;4(10):e2128815. https://pubmed.ncbi.nlm.nih.gov/34643718/
- Pfizer. Pfizer RxPathways Patient Assistance. https://www.pfizer.com/
- HRSA. 340B Drug Pricing Program. https://www.hrsa.gov/opa
- Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395. https://pubmed.ncbi.nlm.nih.gov/19587680/
- Mannick JB, Lamming DW. Targeting the biology of aging with mTOR inhibitors. Lancet Healthy Longev. 2023;4(3):e100-e112. https://pubmed.ncbi.nlm.nih.gov/36750093/
- Zuber J, et al. MTOR inhibitors and dyslipidemia. J Clin Lipidol. 2020;14(4):472-481. https://pubmed.ncbi.nlm.nih.gov/32571723/
- McCormack FX, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis (MILES trial). N Engl J Med. 2011;364(17):1595-1606. https://pubmed.ncbi.nlm.nih.gov/21247988/
- KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant. 2009;9(Suppl 3):S1-S155. https://pubmed.ncbi.nlm.nih.gov/19218475/